Evidence map›Paper›PMID 35499624›Full record

ArticleDiabetes2022

Circulating C-Peptide Levels in Living Children and Young People and Pancreatic β-Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration.

Alice L J Carr, Jamie R J Inshaw, Christine S Flaxman, Pia Leete, Rebecca C Wyatt, Lydia A Russell, Matthew Palmer, Dmytro Prasolov, Thomas Worthington, Bethany Hull and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. New and emerging therapies in type 1 diabetes mellitus.The Journal of clinical investigation · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. The evolution of C-peptide's role in diabetes care.Current opinion in endocrinology, diabetes, and obesity · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Alice L J CarrInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.ORCID 0000-0003-0704-8843
Jamie R J InshawJDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, U.K.
Christine S FlaxmanInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Pia LeeteInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Rebecca C WyattInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Lydia A RussellInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Matthew PalmerInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Dmytro PrasolovInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Thomas WorthingtonInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Bethany HullInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.
Linda S WickerJDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, U.K.
David B DungerDepartment of Paediatrics, Addenbrooke's Hospital, University of Cambridge, Cambridge, U.K.ORCID 0000-0002-2566-9304
Richard A OramInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.ORCID 0000-0003-3581-8980
Noel G MorganInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.ORCID 0000-0003-1537-8113
John A ToddJDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, U.K.
Sarah J RichardsonInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.ORCID 0000-0002-1160-6062
Rachel E J BesserJDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, U.K.
University of Exeter · GBCentre for Human Genetics · GBAddenbrooke's Hospital · GB

Funding

Department of HealthWellcome TrustWellcome Trust 107212/A/15/Z
6 · The paper itself

Abstract

C-peptide declines in type 1 diabetes, although many long-duration patients retain low, but detectable levels. Histological analyses confirm that β-cells can remain following type 1 diabetes onset. We explored the trends observed in C-peptide decline in the UK Genetic Resource Investigating Diabetes (UK GRID) cohort (N = 4,079), with β-cell loss in pancreas donors from the network for Pancreatic Organ donors with Diabetes (nPOD) biobank and the Exeter Archival Diabetes Biobank (EADB) (combined N = 235), stratified by recently reported age at diagnosis endotypes (<7, 7-12, ≥13 years) across increasing diabetes durations. The proportion of individuals with detectable C-peptide declined beyond the first year after diagnosis, but this was most marked in the youngest age group (<1-year duration: age <7 years: 18 of 20 [90%], 7-12 years: 107 of 110 [97%], ≥13 years: 58 of 61 [95%] vs. 1-5 years postdiagnosis: <7 years: 172 of 522 [33%], 7-12 years: 604 of 995 [61%], ≥13 years: 225 of 289 [78%]). A similar profile was observed in β-cell loss, with those diagnosed at younger ages experiencing more rapid loss of islets containing insulin-positive (insulin+) β-cells <1 year postdiagnosis: age <7 years: 23 of 26 (88%), 7-12 years: 32 of 33 (97%), ≥13 years: 22 of 25 (88%) vs. 1-5 years postdiagnosis: <7 years: 1 of 12 (8.3%), 7-12 years: 7 of 13 (54%), ≥13 years: 7 of 8 (88%). These data should be considered in the planning and interpretation of intervention trials designed to promote β-cell retention and function.

Indexed as

Diabetes Mellitus, Type 1Insulin-Secreting CellsAdolescentChildC-PeptideHumansInfantPancreasTissue DonorsC-Peptide

Identifiers

PMID35499624
PMCPMC9233242
OpenAlexW4225278825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.